BR112020003976A8 - Vírus adeno-associado (aav) com domínio fosfolipase modificado - Google Patents

Vírus adeno-associado (aav) com domínio fosfolipase modificado

Info

Publication number
BR112020003976A8
BR112020003976A8 BR112020003976A BR112020003976A BR112020003976A8 BR 112020003976 A8 BR112020003976 A8 BR 112020003976A8 BR 112020003976 A BR112020003976 A BR 112020003976A BR 112020003976 A BR112020003976 A BR 112020003976A BR 112020003976 A8 BR112020003976 A8 BR 112020003976A8
Authority
BR
Brazil
Prior art keywords
modified
aav
adeno
associated virus
sequence
Prior art date
Application number
BR112020003976A
Other languages
English (en)
Other versions
BR112020003976A2 (pt
Inventor
STRINGS-UFOMBAH Vanessa
KAO Shih-Chu
W Roelvink Petrus
Original Assignee
Benitec Biopharma Ltd
Benitec Biopharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Biopharma Ltd, Benitec Biopharma Pty Ltd filed Critical Benitec Biopharma Ltd
Publication of BR112020003976A2 publication Critical patent/BR112020003976A2/pt
Publication of BR112020003976A8 publication Critical patent/BR112020003976A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/015Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A presente divulgação refere-se geralmente ao vírus adeno-associado (AAV) modificado de sorotipos diferentes do sorotipo 2, que possuem uma proteína de capsídeo viral com uma sequência da subunidade 1 (VP1) que é modificada em relação à sequência do tipo selvagem correspondente. Em particular, os AAVs modificados da divulgação compreendem substituições de aminoácidos específicas de sítio no domínio fosfolipase A2 (PLA2) e sequência de flanqueamento em relação à sequência de tipo selvagem correspondente que melhora a funcionalidade do AAV quando produzido em células de inseto. A presente divulgação também se refere a métodos de produção dos AAVs modificados, reagentes para os mesmos, sistemas de expressão de baculovírus e células de inseto para a produção dos referidos AAVs modificados.
BR112020003976A 2017-08-31 2018-08-30 Vírus adeno-associado (aav) com domínio fosfolipase modificado BR112020003976A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553028P 2017-08-31 2017-08-31
US62/553,028 2017-08-31
PCT/IB2018/056651 WO2019043630A1 (en) 2017-08-31 2018-08-30 ADENO-ASSOCIATED VIRUS (AAV) WITH MODIFIED PHOSPHOLIPASE DOMAIN

Publications (2)

Publication Number Publication Date
BR112020003976A2 BR112020003976A2 (pt) 2020-09-01
BR112020003976A8 true BR112020003976A8 (pt) 2023-02-28

Family

ID=65525064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003976A BR112020003976A8 (pt) 2017-08-31 2018-08-30 Vírus adeno-associado (aav) com domínio fosfolipase modificado

Country Status (12)

Country Link
US (1) US11499141B2 (pt)
EP (1) EP3676381A4 (pt)
JP (1) JP7360382B2 (pt)
KR (1) KR102612563B1 (pt)
CN (1) CN111183224B (pt)
AU (1) AU2018323049A1 (pt)
BR (1) BR112020003976A8 (pt)
CA (1) CA3074042A1 (pt)
IL (1) IL272972A (pt)
TW (1) TWI802584B (pt)
UY (1) UY37863A (pt)
WO (1) WO2019043630A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018139634A1 (ja) * 2017-01-30 2018-08-02 学校法人日本医科大学 アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体
US11499141B2 (en) 2017-08-31 2022-11-15 Benitec IP Holdings Inc. Adeno-associated virus (AAV) with modified phospholipase domain
JP7389040B2 (ja) * 2018-01-17 2023-11-29 メイラジーティーエックス・ユーケー・ザ・セカンド・リミテッド 遺伝子治療のための修飾rAAVキャプシドタンパク質
CN113631706A (zh) 2019-02-28 2021-11-09 贝尼泰克知识产权控股股份有限公司 用于治疗眼咽肌营养不良(opmd)的组合物和方法
CN111349148A (zh) * 2020-03-13 2020-06-30 辉大(上海)生物科技有限公司 一种腺相关病毒载体及其用途
WO2021225921A1 (en) * 2020-05-04 2021-11-11 The University Of North Carolina At Chapel Hill Modified adeno-associated virus vectors that evade neutralizing antibodies and uses thereof
CN111825772B (zh) * 2020-07-30 2023-10-20 中国科学院精密测量科学与技术创新研究院 具有变异衣壳蛋白的腺相关病毒及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072364A2 (en) 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
WO2009137006A2 (en) * 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
CN102071206A (zh) * 2010-10-22 2011-05-25 中山大学 一种腺相关病毒衣壳蛋白基因、相应的蛋白及其应用
US11499141B2 (en) 2017-08-31 2022-11-15 Benitec IP Holdings Inc. Adeno-associated virus (AAV) with modified phospholipase domain

Also Published As

Publication number Publication date
KR102612563B1 (ko) 2023-12-11
TWI802584B (zh) 2023-05-21
UY37863A (es) 2019-03-29
EP3676381A1 (en) 2020-07-08
EP3676381A4 (en) 2021-06-02
TW201920676A (zh) 2019-06-01
US11499141B2 (en) 2022-11-15
JP7360382B2 (ja) 2023-10-12
BR112020003976A2 (pt) 2020-09-01
AU2018323049A1 (en) 2020-04-16
CN111183224A (zh) 2020-05-19
KR20200058427A (ko) 2020-05-27
JP2020533973A (ja) 2020-11-26
CN111183224B (zh) 2024-02-23
CA3074042A1 (en) 2019-03-07
US20200190481A1 (en) 2020-06-18
WO2019043630A1 (en) 2019-03-07
IL272972A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
BR112020003976A8 (pt) Vírus adeno-associado (aav) com domínio fosfolipase modificado
Gu et al. Novel reassortant highly pathogenic avian influenza (H5N5) viruses in domestic ducks, China
BR112017005892A2 (pt) variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
BR112018003665A2 (pt) métodos e composições para vetores virais de evasão de anticorpo
CL2020000728A1 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas.
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112018071180A2 (pt) métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
Soda et al. H9N2 influenza virus acquires intravenous pathogenicity on the introduction of a pair of di-basic amino acid residues at the cleavage site of the hemagglutinin and consecutive passages in chickens
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
CR20190127A (es) Métodos para detectar aav
BR112017017028A2 (pt) rnai variante
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
BR112019002904A2 (pt) métodos e composições para transferência gênica direcionada
PH12020550117A1 (en) Variant rnai
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos
Mostafa et al. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs
Park et al. Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A (H7N9) virus in guinea pigs
Poole et al. Influenza A virus polymerase is a site for adaptive changes during experimental evolution in bat cells
JOP20220043A1 (ar) بروتين كابسيد vp1 معدل معزول من aav5
BR112022016965A2 (pt) Polipeptídeos e vetores de capsídeo do vírus adenoassociado
BR112021020391A2 (pt) Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas
BR112015030419A2 (pt) células aviárias para a produção de vírus melhorado

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BENITEC BIOPHARMA PTY LTD (AU)

B25G Requested change of headquarter approved

Owner name: BENITEC BIOPHARMA PTY LTD (AU)

B25A Requested transfer of rights approved

Owner name: BENITEC IP HOLDINGS INC. (US)